Following a recent approval by Chinese drug regulators, CanSino Biologics has launched its inhaled COVID-19 vaccine as a booster dose — the first of its kind.
The National Medical Products Administration of China approved Beijing-based CanSinoBIO's recombinant vaccine last month, branded as Convidecia Air, marking the the first global approval of an inhaled vaccine.
Utilizing the same adenovirus vector technological platform as the drugmaker's intramuscular vaccine, Convidecia, the Convidecia Air vaccine provides a non-invasive option that uses a nebulizer to change liquid into an aerosol for inhalation through the mouth. According to CanSino, the needle-free option can effectively induce comprehensive immune protection in response to SARS-CoV-2 after just one breath.
This past January, CanSino shared a phase 1/2 study that showed that boosting the inactivated vaccine with Convidecia Air stimulated a strong mucosal immune response. According to the findings, the level of RBD-specific IgA-binding antibody was detected in the serum of the subjects 14 days after vaccination.
